Trial Profile

Bevacizumab and Endothelium Dependent Vasodilation.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Acetylcholine; Sodium nitroprusside
Indications Brain cancer; Breast cancer; Cancer; Carcinoid tumour; Colorectal cancer; Diffuse large B cell lymphoma; Fallopian tube cancer; Gastric cancer; Glioblastoma; Haemangiosarcoma; Head and neck cancer; Liver cancer; Malignant melanoma; Mesothelioma; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Renal cancer; Solid tumours
Focus Pharmacodynamics
Acronyms BVZAch

Most Recent Events

10 Jan 2013 Biomarkers information updated
10 Aug 2011 Planned end date changed from Nov 2010 to Nov 2011 as reported by ClinicalTrials.gov.
25 Nov 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com